Racing China to the Starting Line: What the FDA's New IND Pilot Really Means for Drug Development

On September 15, 2026, the FDA formally opened its Expedited Investigational New Drug Pilot Program for applications, accepting submissions through October 30. The announcement was framed as a milestone in Operation TrialBlazer, the HHS-wide initiative launched in June to reverse the steady migration of early-stage clinical research away from the United States. The language was confident. The ambition was real. But the gap between what the pilot promises and what it can actually deliver is worth examining carefully, because the problem it is trying to solve is considerably larger than the mechanism it has chosen to address it.

The Numbers Behind the Urgency

The competitive case for reform is not manufactured. China surpassed the United States in global Phase 1 trial share in 2021. By 2024, China accounted for 39 percent of all registered clinical trials globally, with more than 7,100 active studies. The average time between a pre-IND meeting request and formal IND submission in the United States sits at 380 days, with some programs waiting nearly 700 days. Australia can move a drug from final protocol submission to trial initiation in fewer than 70 days. China has committed to initiating trials within 12 weeks of IND submission. The United States, by contrast, can add up to 13 months of additional delay after an IND is granted, just from IRB review and site contracting, before a single patient is enrolled.

These are not abstract statistics. They represent investment decisions, intellectual property flows, and first-in-human data that are being generated outside the United States and then licensed back to American companies at significant cost. HHS estimates that global companies spent over $137 billion licensing China-based assets in 2025 alone. If current trends continue, drugs developed by Chinese biotech companies are projected to account for 35 percent of FDA approvals by 2040. That is the context in which Operation TrialBlazer was designed, and it is a context that makes the urgency of the initiative entirely understandable.

What the Pilot Actually Does

The Expedited IND Pilot pairs drug sponsors with a new class of entity called Qualified Research Institutions, or QRIs, which can include academic medical centers, contract research organizations, healthcare networks, and regulatory advisors. The QRI reviews the sponsor's Phase 1 protocol components on a rolling basis before formal IND submission, providing advisory input on pharmacology and toxicology, chemistry manufacturing and controls, and clinical design. The FDA then reviews those components on a rolling basis as well, potentially allowing a sponsor to receive a safe-to-proceed notification before the standard 30-day review clock has fully elapsed.

The FDA will select approximately eight to ten sponsor-QRI pairs for the pilot, prioritizing novel investigational products for diseases with severe unmet need and sponsors who have already generated sufficient preclinical data. The program is voluntary. QRI recommendations are advisory only. The FDA retains full regulatory authority and the ability to issue clinical holds at any point. The 30-day review clock itself is unchanged. What changes is the quality and completeness of what arrives at the FDA's door, and the degree to which IRB review and site contracting can begin in parallel with IND development rather than sequentially after it.

Where the Real Delays Live

The honest tension in the pilot's design is that the FDA's own 30-day review clock is not the primary source of the delays that are driving research offshore. The 380-day average from pre-IND meeting request to IND submission reflects sponsor-side preparation time, regulatory uncertainty about what data is actually required, and the structural friction of a system that has historically communicated its expectations poorly. A former FDA oncology division director quoted in trade press put it plainly: the FDA is not the primary source of most delays in early phase clinical trials. A former FDA chief medical officer went further, arguing that until the site-level issues around IRB review and contract negotiation are resolved, regulatory speed improvements will have limited impact on overall timelines.

The pilot acknowledges this. The HHS roadmap notes that 45 percent of protocol amendments are somewhat or completely avoidable, and that simplifying protocols and reducing amendments could reduce the estimated cost of bringing a drug to market by up to 22 percent. The FDA is also pursuing IRB reform, including potential rulemaking to require a single IRB of record for multi-site studies, and has launched a Phase 1 Contact Center to provide real-time answers to sponsor questions. These are the kinds of structural changes that could move the needle on the delays that actually matter. The QRI pilot is a useful complement to that work, but it is not a substitute for it.

The Equity Question the FDA Is Asking Itself

One of the more striking features of the pilot's design is that the FDA has publicly posed the question of whether it could create inequitable access. The concern is straightforward: if QRI engagement requires fees, and if the initial pool of qualified institutions is small, larger and better-resourced sponsors will be positioned to secure QRI partnerships before smaller companies can. The FDA has not established fees for the pilot period, but it has indicated that post-pilot, sponsors will pay QRIs directly, outside FDA's involvement. Arnold and Porter analysts have flagged the risk of a race for QRI relationships that disadvantages the smaller biotechs that are often the source of the most innovative early-stage science.

This is not a reason to abandon the pilot. It is a reason to design the post-pilot framework carefully, with explicit attention to how smaller sponsors and academic investigators can access the system without being priced out of it. The FDA's willingness to ask the question publicly is itself a signal of institutional seriousness about the equity dimension of regulatory reform.

What Success Would Actually Look Like

The pilot's stated goal is to reduce Phase 1 trial timelines by six months to a year. That is a meaningful target if it is achieved, but the mechanism for achieving it runs through better-prepared IND submissions and parallel IRB work, not through a shorter FDA review clock. The FDA's updated Phase 1 CMC guidance, which clarifies what chemistry and manufacturing data is actually required at the IND stage rather than leaving sponsors to guess, is arguably the more immediately impactful action in the TrialBlazer package. The agency estimates that focusing on phase-appropriate requirements alone could save sponsors six to twelve months of development time, without any QRI involvement at all.

The deeper question Operation TrialBlazer is trying to answer is whether the United States can rebuild its position as the preferred destination for early clinical research before the structural advantages it has historically held are fully eroded. The answer will not come from a pilot program that selects eight to ten sponsor-QRI pairs. It will come from whether the IRB reform rulemaking advances, whether the single-IRB model becomes standard for multi-site studies, whether the Phase 1 Contact Center actually reduces the uncertainty that drives sponsors to over-prepare, and whether the FDA can sustain the institutional commitment to transparency and speed that the TrialBlazer roadmap describes. The pilot is a test of whether the model works. The harder work is everything that surrounds it.